ERBB2 and breast cancer: Genomic profiling of patients with ERBB2-positive BC before and after trastuzumab plus chemotherapy revealed that NOTCH2 and GATA3 mutations, along with others, were clonally enriched and/or acquired in the post-treatment samples (30), which could be also relevant in our case.